Search results
Results from the WOW.Com Content Network
Dulaglutide is another GLP-1 injection available under the brand name Trulicity®. This medication is FDA-approved for type 2 diabetes but is sometimes prescribed off-label for weight loss.
[11] [16] Tirzepatide is administered via subcutaneous injections (under the skin). [10] [13] It is sold under the brand name Mounjaro for diabetes treatment, [10] and Zepbound for weight loss and treatment of obstructive sleep apnea. [11] [17] Tirzepatide is a gastric inhibitory polypeptide analog and GLP-1 receptor agonist. [11]
For many biologics (e.g., monoclonal antibodies), injection site reactions are the most common adverse effect of the drug, and have been reported to have an incidence rate of 0.5–40%. [ 2 ] In trials of subcutaneous administration of oligonucleotides , between 22 and 100% of subjects developed reactions depending on the oligonucleotide.
Zepbound, like other GLP-1 agonists, can cause uncomfortable side effects, including gastrointestinal problems. According to the FDA’s drug label, side effects include: Nausea.
PHOTO: An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, March 28, 2024. (Shelby Knowles/Bloomberg via Getty Images) MORE: Zepbound leads to more weight loss ...
Subcutaneous injection sites. Commonly used injection sites include: [3]: 723 The outer area of the upper arm. The abdomen, avoiding a 2-inch circle around the navel. The front of the thigh, between 4 inches from the top of the thigh and 4 inches above the knee. The upper back. The upper area of the buttock, just behind the hip bone.
The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.
Dulaglutide, sold under the brand name Trulicity among others, [8] is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. [9] [10] It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.